|
- Geron | Working to change the course of blood cancers
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives
- Our tireless pursuit | Geron
With a seasoned leadership team with world-class expertise spanning research, clinical development, regulatory, manufacturing and commercial experience in hematologic malignancies, Geron is prepared to deliver on our mission to change lives by changing the course of blood cancer
- Careers | Geron
Geron is always accepting applications for employment opportunities Click on the ‘ Explore Open Positions ’ link above to find all of the open positions for which we are currently recruiting
- Geron Corporation - Investors Media
Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia
- Advancing how blood cancers are treated | Geron
Scientific research has shown that telomerase activity is increased in malignant stem and progenitor cells in the bone marrow Inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells Geron is exploring the broad potential of telomerase inhibition across multiple hematologic malignancies
- Clinical trials exploring imetelstat | Geron
Geron sponsored trials IMpactMF, our pivotal Phase 3 clinical trial in JAK inhibitor relapsed refractory MF, is an open label, 2:1 randomized, controlled clinical trial of imetelstat to evaluate a potential improvement in overall survival compared to best available therapy
- Our story continues to evolve | Geron
Geron is founded by Mike West, a pioneer in stem cell, cellular aging and telomerase research, and Alex Barkas, a venture capitalist who at the time was a partner at Kleiner Perkins Caufield Byers
- Geron Corporation - Investors Media - Press Releases
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS
|
|
|